| Date | Title | Description |
| 27.08.2026 | Oncoinvent presents first half 2026 results | Oncoinvent presents first half 2026 results
Thu, Aug 27, 2026 07:00 CET Report this content
Oslo, Norway, 27 August 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate ca... |
| 17.08.2026 | Invitation to First-Half 2026 webcast - Thursday 27 August 2026 | Invitation to First-Half 2026 webcast - Thursday 27 August 2026
Mon, Aug 17, 2026 07:00 CET Report this content
Oslo, Norway, 17 August 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceut... |
| 11.08.2026 | Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine | Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine
Tue, Aug 11, 2026 07:00 CET Report this content
Clinical dosimetry results from Phase 1 studies of Radspherin® in ovarian and colorectal canc... |
| 18.06.2026 | Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin[®] | Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin[®]
Thu, Jun 18, 2026 07:00 CET Report this content
Strong recruitment momentum demonstrated in 2026
Year-to-date recruitment has already surpassed t... |
| 20.05.2026 | Oncoinvent ASA: Grant of share options to member of the Board following AGM | Oncoinvent ASA: Grant of share options to member of the Board following AGM
Wed, May 20, 2026 20:54 CET Report this content
Oslo, Norway, 20 May 2026: Reference is made to the Annual General Meeting (the “AGM”) of Oncoinvent ASA (the “Compa... |
| 20.05.2026 | Oncoinvent ASA: Minutes from Annual General Meeting | Oncoinvent ASA: Minutes from Annual General Meeting
Wed, May 20, 2026 11:15 CET Report this content
20 May 2026, Oslo Norway: The Annual general meeting of the Company was held today, 20 May 2026, by electronic means through Lumi AGM. All p... |
| 05.05.2026 | Oncoinvent ASA: Share capital decrease completed | Oncoinvent ASA: Share capital decrease completed
Tue, May 05, 2026 10:26 CET Report this content
Oslo, Norway, 5 May 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 8 January 20... |
| 29.04.2026 | Oncoinvent presents corporate update in live webcast | Oncoinvent presents corporate update in live webcast
Wed, Apr 29, 2026 07:00 CET Report this content
Oslo, Norway, 29 April 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to erad... |
| 28.04.2026 | Oncoinvent ASA: Notice of Annual General Meeting | Oncoinvent ASA: Notice of Annual General Meeting
Tue, Apr 28, 2026 12:47 CET Report this content
Oslo, Norway, 28 April 2026 - Oncoinvent ASA (ONCIN), will be holding its Annual General Meeting virtual on 20 May 2026 at 10:00 hours (CEST).
... |
| 23.04.2026 | Oncoinvent ASA: Invitation to business update Wednesday 29 April 2026 | Oncoinvent ASA: Invitation to business update Wednesday 29 April 2026
Thu, Apr 23, 2026 07:00 CET Report this content
Oslo, Norway, 23 April 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharm... |
| 22.04.2026 | Oncoinvent ASA: Annual Report for 2025 | Oncoinvent ASA: Annual Report for 2025
Wed, Apr 22, 2026 16:31 CET Report this content
Oslo, Norway, 22 April 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer c... |
| 19.03.2026 | Oncoinvent secures new patent expanding protection for Radspherin[®] | Oncoinvent secures new patent expanding protection for Radspherin[®]
Thu, Mar 19, 2026 07:00 CET Report this content
First patent from a new patent family granted in China, strengthening the long‑term intellectual property protection for th... |
| 11.03.2026 | Oncoinvent ASA: Grant of share options to the CEO | Oncoinvent ASA: Grant of share options to the CEO
Wed, Mar 11, 2026 22:34 CET Report this content
Oslo, Norway, 11 March 2026: The Board of Directors has today resolved to grant CEO Øystein Soug 31,884 share options in the Company under the... |
| 27.02.2026 | Health Frontiers: Cancer Breakthroughs Meet Policy Crossroads | The landscape of health evolves rapidly. Scientific innovation pushes new boundaries. Policy decisions face intense scrutiny. Recent developments highlight this dynamic tension.
Norway-based Oncoinvent ASA makes significant strides. The bio... |
| 26.02.2026 | Oncoinvent ASA: Second half 2025 results | Oncoinvent ASA: Second half 2025 results
Thu, Feb 26, 2026 07:00 CET Report this content
Oslo, Norway, 26 February 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate can... |
| 17.02.2026 | Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 2026 | Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 2026
Tue, Feb 17, 2026 07:00 CET Report this content
9 of 10 patients at the highest dose remained free from peritoneal recurr... |
| 16.02.2026 | Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026 | Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026
Mon, Feb 16, 2026 07:00 CET Report this content
Oslo, Norway, 16 February 2026: Oncoinvent ASA (ONCIN), a biotech company developing a r... |
| 29.01.2026 | Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial | Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial
Thu, Jan 29, 2026 07:00 CET Report this content
First patient enrolled in newly activated site
Oslo, Norway, 29 January 2026: Oncoinvent, a clinical stage, radiopharma... |
| 20.01.2026 | Oncoinvent ASA: Registration of reverse share split | Oncoinvent ASA: Registration of reverse share split
Tue, Jan 20, 2026 10:47 CET Report this content
Oslo, Norway, 20 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 8 Ja... |
| 19.01.2026 | Oncoinvent ASA: Ex. reverse share split and change of ISIN today | Oncoinvent ASA: Ex. reverse share split and change of ISIN today
Mon, Jan 19, 2026 07:00 CET Report this content
Issuer name: Oncoinvent ASA
Ex. date: 19 January 2026
Type of corporate action: Reverse share split
Other information:
- Revers... |
| 15.01.2026 | Oncoinvent ASA – New share capital registered | Oncoinvent ASA – New share capital registered
Thu, Jan 15, 2026 10:12 CET Report this content
Oslo, Norway, 15 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 8 January ... |
| 14.01.2026 | Oncoinvent ASA: Key information relating to the reverse share split and change of ISIN | Oncoinvent ASA: Key information relating to the reverse share split and change of ISIN
Wed, Jan 14, 2026 15:49 CET Report this content
Oslo, Norway, 14 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent AS... |
| 13.01.2026 | Oncoinvent ASA: Grant of share options to new CFO | Oncoinvent ASA: Grant of share options to new CFO
Tue, Jan 13, 2026 08:12 CET Report this content
Oslo, Norway, 13 January 2026: Reference is made to the announcement made by Oncoinvent ASA ("Oncoinvent" or the "Company"... |
| 08.01.2026 | Oncoinvent ASA: Minutes from Extraordinary General Meeting | Oncoinvent ASA: Minutes from Extraordinary General Meeting
Thu, Jan 08, 2026 13:42 CET Report this content
Oslo, Norway, 8 January 2026: An extraordinary general meeting of the Company was held today, 8 January 2026, by electronic means thr... |
| 22.12.2025 | Oncoinvent ASA: Grant of share options – mandatory notification of trade | Oncoinvent ASA: Grant of share options – mandatory notification of trade
Mon, Dec 22, 2025 18:09 CET Report this content
Oslo, Norway, 22 December 2025: Oncoinvent ASA (“Oncoinvent” or the “Company”) (OSE: ONCOIN), a clinical stage, radioph... |
| 10.12.2025 | Oncoinvent ASA: New share capital registered | Oncoinvent ASA: New share capital registered
Wed, Dec 10, 2025 18:15 CET Report this content
10 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the "Company") on 30 June 2025 and 4... |
| 08.12.2025 | Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology | Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology
Mon, Dec 08, 2025 07:00 CET Report this content
Oslo, Norway, 8 December 2025 - Oncoinvent, a clinical stage, radiopharmaceu... |
| 08.12.2025 | Oncoinvent ASA: Notification of trade – primary insider/close associate | Oncoinvent ASA: Notification of trade – primary insider/close associate
Mon, Dec 08, 2025 06:55 CET Report this content
8 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the "Company&qu... |
| 02.12.2025 | Oncoinvent ASA: Final results of the rights issue | Oncoinvent ASA: Final results of the rights issue
Tue, Dec 02, 2025 12:21 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE... |
| 01.12.2025 | Oncoinvent ASA: Preliminary results of the rights issue | Oncoinvent ASA: Preliminary results of the rights issue
Mon, Dec 01, 2025 18:45 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINIST... |
| 01.12.2025 | Oncoinvent ASA: Last day of the subscription period in the rights issue | Oncoinvent ASA: Last day of the subscription period in the rights issue
Mon, Dec 01, 2025 07:00 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG ... |
| 17.11.2025 | Oncoinvent ASA: Commencement of the subscription period for the Rights Issue | Oncoinvent ASA: Commencement of the subscription period for the Rights Issue
Mon, Nov 17, 2025 06:30 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG ... |
| 03.11.2025 | Mandatory notification of trade | Mandatory notification of trade
Mon, Nov 03, 2025 08:55 CET Report this content
Oslo, 3 November 2025: Reference is made to the stock exchange announcement published by Oncoinvent ASA (the "Company") on 29 October 2025 regarding t... |
| 31.10.2025 | Oncoinvent appoints Dr. Ramzi Amri as new CFO | Oncoinvent appoints Dr. Ramzi Amri as new CFO
Fri, Oct 31, 2025 08:30 CET Report this content
Oncoinvent ASA (OSE: ONCIN) today announces the appointment of Dr. Ramzi Amri, M.D., Ph.D. as Chief Financial Officer (CFO), effective on or aroun... |
| 29.10.2025 | BerGenBio and Oncoinvent – Last day of trading in the shares of Oncoinvent | BerGenBio and Oncoinvent – Last day of trading in the shares of Oncoinvent
Wed, Oct 29, 2025 07:00 CET Report this content
Bergen, 29 October 2025; Reference is made to the joint stock exchange announcement made on 24 October 2025 by BerGen... |
| 29.10.2025 | Merger of BerGenBio and Oncoinvent completed | Merger of BerGenBio and Oncoinvent completed
Wed, Oct 29, 2025 17:35 CET Report this content
Oslo, 29 October 2025 – Reference is made to the previous stock exchange announcements made in connection with the combination of BerGenBio ASA and... |
| 29.10.2025 | BerGenBio and Oncoinvent – Last day of trading in the shares of Oncoinvent | BerGenBio and Oncoinvent – Last day of trading in the shares of Oncoinvent
Wed, Oct 29, 2025 07:00 CET Report this content
Reference is made to the joint stock exchange announcement made on 24 October 2025 by BerGenBio ASA and Oncoinvent AS... |
| 29.10.2025 | Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies | Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies
Wed, Oct 29, 2025 15:16 CET Report this co... |
| 28.10.2025 | BerGenBio ASA: Approval and publication of prospectus | BerGenBio ASA: Approval and publication of prospectus
Tue, Oct 28, 2025 10:42 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRA... |
| 24.10.2025 | BerGenBio and Oncoinvent – Key Dates for Completion of Merger | BerGenBio and Oncoinvent – Key Dates for Completion of Merger
Fri, Oct 24, 2025 07:59 CET Report this content
Bergen, Norway and Oslo, Norway, 24 October 2025 – Reference is made to the joint stock exchange announcement on 30 June 2025 by B... |
| 24.10.2025 | BerGenBio and Oncoinvent – Key Dates for Completion of Merger | BerGenBio and Oncoinvent – Key Dates for Completion of Merger
Fri, Oct 24, 2025 08:00 CET Report this content
Bergen, Norway and Oslo, Norway, 24 October 2025 – Reference is made to the joint stock exchange announcement on 30 June 2025 by B... |
| 08.10.2025 | Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer | Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer
Wed, Oct 08, 2025 07:00 CET Report this content
New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression
Oncoinvent ... |
| 17.09.2025 | BerGenBio ASA: Updated Key Information related to the contemplated Rights Issue | BerGenBio ASA: Updated Key Information related to the contemplated Rights Issue
Wed, Sep 17, 2025 08:56 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HO... |
| 17.09.2025 | BerGenBio ASA: Updated information regarding the contemplated Rights Issue and Merger | BerGenBio ASA: Updated information regarding the contemplated Rights Issue and Merger
Wed, Sep 17, 2025 08:55 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, ... |
| 29.08.2025 | Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement | Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement
Fri, Aug 29, 2025 07:00 CET Report this content
Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and Onc... |
| 27.08.2025 | Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer | Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer
Wed, Aug 27, 2025 07:00 CET Report this content
Oncoinvent reports continued progress in the ongoing Phase 2 trial in ov... |
| 22.08.2025 | Oncoinvent ASA invites to a webcast presentation of 1H 2025 on Wednesday 27 August 2025 | Oncoinvent ASA invites to a webcast presentation of 1H 2025 on Wednesday 27 August 2025
Fri, Aug 22, 2025 12:22 CET Report this content
Oncoinvent will present operational and financial update for the first half of 2025 on Wednesday 27 Augu... |
| 20.08.2025 | BerGenBio First half results 2025 | BerGenBio First half results 2025
Wed, Aug 20, 2025 07:00 CET Report this content
Bergen, Norway, 20 August 2025 – BerGenBio ASA (OSE: BGBIO today announced financial results for the first half 2025.
Highlights, including post period:
In Fe... |
| 05.08.2025 | BerGenBio ASA – Updated key information related to the rights issue | BerGenBio ASA – Updated key information related to the rights issue
Tue, Aug 05, 2025 16:49 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPEC... |
| 04.08.2025 | BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue | BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue
Mon, Aug 04, 2025 13:40 CET Report this content
Bergen, 4 August 2025: Reference is made to the joint stock exchange announcement made on 30 June 2025 by Ber... |
| 04.08.2025 | Oncoinvent shareholders approve the merger plan with BerGenBio | Oncoinvent shareholders approve the merger plan with BerGenBio
Mon, Aug 04, 2025 13:53 CET Report this content
Oslo, Norway, 4 August 2024 – Reference is made to the joint stock exchange announcement made on 30 June 2025 by Oncoinvent ASA (... |
| 03.07.2025 | Oncoinvent ASA: Notice of Extraordinary General Meeting | Oncoinvent ASA: Notice of Extraordinary General Meeting
Thu, Jul 03, 2025 15:45 CET Report this content
An extraordinary general meeting in Oncoinvent ASA will be held on 4. August 2025 at 12:00
CEST. The meeting will be held in Gullhaugvei... |
| 01.07.2025 | The Dance of Capital: BerGenBio and Hacksaw's Bold Moves in the Market | In the world of finance, the rhythm of capital flows can be both exhilarating and daunting. Recently, two companies, BerGenBio ASA and Hacksaw, have taken significant steps that illustrate this dance. Each move is a calculated step toward g... |
| 30.06.2025 | Announcement of fully underwritten rights issue | Announcement of fully underwritten rights issue
Mon, Jun 30, 2025 22:05 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE R... |
| 30.06.2025 | BerGenBio ASA – Key information related to the rights issue | BerGenBio ASA – Key information related to the rights issue
Mon, Jun 30, 2025 22:29 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMI... |
| 18.06.2025 | Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases | Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases
Wed, Jun 18, 2025 07:05 CET Report this content
Data demonstrate sustained peritoneal disease control and reinfo... |
| 03.05.2025 | Oncoinvent's Radspherin®: A Beacon of Hope in Ovarian Cancer Treatment | In the world of cancer treatment, hope often flickers like a candle in the dark. Oncoinvent ASA, a clinical-stage biotechnology company, has recently reported promising results from its Phase 1 trial of Radspherin®, a novel radiopharmaceuti... |
| 28.04.2025 | Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression | Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression
Mon, Apr 28, 2025 08:07 CET Report this content
Oncoinvent ASA, ... |
| 28.04.2025 | Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update | Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update
Mon, Apr 28, 2025 08:12 CET Report this content
In connection with the release of the first quarter 2025 company update, Oncoinvent invites for a
Live streamed of quarterl... |
| 01.03.2025 | Navigating the Waters of Innovation: Oncoinvent and Esmaeilzadeh Holding's Financial Journeys | In the world of finance and biotechnology, companies often find themselves at a crossroads. They must balance innovation with fiscal responsibility. Two recent reports from Oncoinvent ASA and Esmaeilzadeh Holding AB illustrate this delicate... |
| 01.03.2025 | Navigating the Waters of Change: Oncoinvent and Avida's Transformative Journeys | In the world of finance and biotechnology, change is the only constant. Two companies, Oncoinvent ASA and Avida Finans AB, recently showcased their transformative journeys in their fourth quarter and year-end reports. Both firms are navigat... |
| 27.02.2025 | Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort of the phase 2 trial of Radspherin® in Ovarian Cancer Patients | Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort of the phase 2 trial of Radspherin® in Ovarian Cancer Patients
Thu, Feb 27, 2025 07:04 CET Report this content
Oncoinvent, a clinical-stage radiopharmaceutical ... |
| 27.02.2025 | Oncoinvent ASA: Fourth Quarter 2024 Update and Results | Oncoinvent ASA: Fourth Quarter 2024 Update and Results
Thu, Feb 27, 2025 07:34 CET Report this content
Oncoinvent ASA (OSE: ONCIN) a clinical stage 2 radiopharmaceutical company developing novel radiopharmaceutical therapies against cancer,... |
| 20.02.2025 | Oncoinvent ASA: Invitation to Result Presentation Q4 2024 | Oncoinvent ASA: Invitation to Result Presentation Q4 2024
Thu, Feb 20, 2025 10:26 CET Report this content
Oslo, Norway 20, February 2025
In connection with the release of the results for the full year and fourth quarter 2024, Oncoinvent inv... |
| 05.12.2024 | Oncoinvent ASA announces oversubscribed private placement | Oncoinvent ASA announces oversubscribed private placement
Thu, Dec 05, 2024 11:50 CET Report this content
Oncoinvent ASA ("Oncoinvent" or the "Company") is pleased to announce that it has today successfully completed the... |
| 11.11.2024 | Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatoses | Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatoses
Mon, Nov 11, 2024 08:49 CET Report this content
Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy a... |
| 10.10.2024 | Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients | Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients
Thu, Oct 10, 2024 11:09 CET Report this content
Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative... |
| 27.06.2024 | BioStock: Fast Track designation facilitates development of Oncoinvent’s Radspherin | BioStock: Fast Track designation facilitates development of Oncoinvent’s Radspherin
Thu, Jun 27, 2024 08:14 CET Report this content
The FDA has granted Fast Track to Oncoinvent for its radiopharmaceutical Radspherin as a treatment for perit... |
| 29.06.2021 | Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round | Norwegian radiopharmaceutical company announces successful closing of a
private placement that will allow the company to initiate the next phase of
clinical development of its lead product candidate Radspherin®
Norway Oncoinvent AS, a cl... |
| 09.04.2021 | Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin® | 7MBq dose of Radspherin® determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study
Oncoinvent AS, a clinical stage company advancing a pipeline of radio... |
| 11.01.2021 | Oncoinvent Announces Advancement of Radspherin® to Final Dose Level Cohort in Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients | Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-002 study to fourth and final cohort dose level cohort
Oslo 11, January 2020
Oncoinvent AS, a clinical stage company advancing a pipeline o... |
| 29.10.2020 | Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial | Safety review of second dose-level cohort allows study to advance to third cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.
Oncoinvent AS, a clinical stage radiopharmaceutical company devel... |
| 04.09.2020 | Oncoinvent Advances Radspherin[®] to Second Dose Level in Ongoing Phase 1 Clinical Trial | FRI, SEP 04, 2020 09:19 CET
Safety review of first dose-level cohort allows progression to second cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.
Oslo 4. September 2020
Oncoinvent AS, a ... |
| 11.06.2020 | Oncoinvent Announces Dosing of First Patient with Radspherin® in a Second Phase 1 Clinical Trial | Radiopharmaceutical company starts first-in-human trial in a second patient population; ovarian cancer patients suffering from peritoneal carcinomatosis
Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisot... |
| 02.06.2020 | Oncoinvent Announces Dosing of First Patient with Radspherin® in Phase 1 Clinical Trial | Press Release 02.2020: Radiopharmaceutical company starts first-in-human trial in colorectal patients suffering from peritoneal carcinomatosis
Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based ... |
| 27.05.2020 | Oncoinvent Raises 40M NOK Financing Round | Oncoinvent AS, an Oslo, Norway-based developer of new products to provide treatment options to cancer patients, completed a 40m NOK round of financing.
The round, which brought total funding raised to date to 268m NOK, was led by Hadean Ven... |
| 14.02.2017 | Term Sheet — Tuesday, February 14 | OPEN MIC
It’s feedback time.
Paid Content Securing the enterprise without boundaries From ExtraHop
…Mike Moritz’s op-ed against carried interest, private equity and Stephen Schwarzman:
Anon writes: I have become slightly appalled with how s... |
| 13.02.2017 | Oncoinvent Raises $25M in Equity Funding | Oncoinvent, an Oslo, Norway-based developer of cancer therapeutics, raised around $25m in new equity funding.
Backers included Geveran Trading, Canica, CGS Holding, Helene Sundt and Must Invest.
Led by Jan A. Alfheim, CEO, Oncoinvent is dev... |
| - | Oncoinvent | “Committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients Latest news and press releases ALL202420232022202120202019201820172016 28. Aug. 2024 Oncoinvent Appoints Oystein Soug as C... |
